Neuropathological and molecular aspects of low-grade and high-grade gliomas.

Gliomas are the most frequent primary brain tumors. They are derived from glial cells of astrocytic, oligodendroglial and ependymal origin. According to the WHO classification of brain tumors gliomas are divided in low-grade (grades I and II) and high-grade (grades III and IV) tumors. Low-grade tumors are well-differentiated, slow-growing lesions. Grade I tumors are well-circumscribed and often surgically curable, whereas grade II tumors are diffuse, infiltrating lesions with a marked potential over time for progression towards a high-grade malignant tumor. The optimal management of low-grade gliomas is still debated. Important prognostic factors such as histology, grade and location of the tumor, age and functional status of the patient, must be taken into consideration to select the most appropriate treatment. Major advances in the molecular genetic assessment of brain tumors and of gliomas in particular have lead to the identification of several molecular markers playing a crucial role in the development of gliomas and in their malignant transformation. Some of those markers were found very useful to assist in the histological diagnosis and to predict survival and response to therapy. A combined deletion of chromosomes arms 1p and 19q can be found in more than 50% of Grade II and III oligodendrogliomas and has been associated with chemosensitivity and a better prognosis. Once limited to the field of research, molecular biology has now entered the daily neuropathological practice and will undoubtedly play an increasing role in future classification and treatment of brain tumors.

[1]  M. J. van den Bent,et al.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors. , 2003, Neuro-oncology.

[2]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[3]  I. Whittle,et al.  The dilemma of low grade glioma , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  David N Louis,et al.  Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro‐Oncology , 2003, Journal of neuropathology and experimental neurology.

[5]  K. Aldape,et al.  Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Fimmers,et al.  Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival , 2004, Brain pathology.

[8]  M. J. van den Bent,et al.  Temozolomide chemotherapy in recurrent oligodendroglioma , 2001, Neurology.

[9]  K. Roth,et al.  Prognostic Value of 1p, 19q, 9p, 10q, and EGFR‐FISH Analyses in Recurrent Oligodendrogliomas , 2004, Journal of neuropathology and experimental neurology.

[10]  R. Mccomb,et al.  Pathology and Genetics of Tumours of the Nervous System , 1998 .

[11]  G. Leikauf,et al.  Microarrays as cancer keys: an array of possibilities. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Louis The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.

[13]  R. DePinho,et al.  Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.

[14]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Ramaioli,et al.  Long-term outcome of oligodendrogliomas , 2004, Neurology.

[16]  R. Sevick,et al.  How often are nonenhancing supratentorial gliomas malignant? A population study , 2002, Neurology.

[17]  A. Twijnstra,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Presenting Symptoms and Imaging of Grade Ii Astrocytoma Supratentorial Grade Ii Astrocytoma: Biological Features and Clinical Course , 2022 .

[18]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[19]  S. Rempel Molecular biology of central nervous system tumors. , 1998, Current opinion in oncology.

[20]  D. Louis,et al.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. , 2001, The American journal of pathology.